Boston, MA -- (SBWIRE) -- 05/19/2012 -- BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic competition as a result of the patent cliff, we expect Germany to remain attractive to innovative drugmakers. In 2011, Germany's drug market was the fourth largest globally after the US, Japan and China. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will continue to bring in substantial income for companies operating in the country.
Headline Expenditure Projections
- Pharmaceuticals: EUR39.39bn (US$55.15bn) in 2011 to EUR38.40bn (US$51.46bn) in 2012; -2.5% decline in local currency terms and +6.7% in US dollar terms.
- Healthcare: EUR275.10bn (US$385.15bn) in 2011 to EUR280.97bn (US$376.49bn) in 2012; +2.1% growth in local currency terms and -2.2% in US dollar terms.
- Medical devices: EUR14.97bn (US$22.96bn) in 2011 to EUR15.64bn (US$20.95bn) in 2012; +4.5% growth in local currency terms and no growth in US dollar terms. Forecasts unchanged from Q411.
View Full Report Details and Table of Contents
Business Environment Rating: In our Pharmaceutical and Healthcare Business Environment Ratings (BERs) for Q212, Germany is second, behind Switzerland. Despite the tough pricing and reimbursement conditions and the effects of patent expirations, Germany remains one of the largest global pharmaceutical markets, which will continue to prop up its rewards score.
Key Trends And Developments
- In December 2011, positive news for multinational drugmaker AstraZeneca, the company's Brilique (ticagrelor) for patients with acute coronary syndromes (ACS) has passed Germany's new cost-benefit assessment. Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate receptor antagonist and the first in a new class of drugs, cyclo-pentyl-triazolo-pyrimidines (CPTPs), which are chemically distinct from thienopyridines such as BMS/Sanofi's Plavix (clopidogrel) and Eli Lilly/Daiichi Sankyo's Effient (prasugrel).
- In January 2012, in negative news for multinational drugmakers Eli Lilly and Boehringer Ingelheim, Trajenta (linagliptin) for patients with type 2 diabetes did not pass the Institute for Quality and Efficiency in Healthcare (IQWiG)'s assessment (a part of the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) cost-benefit assessment)
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Kenya Pharmaceuticals & Healthcare Report Q2 2012
- Oman Pharmaceuticals & Healthcare Report Q2 2012
- Turkey Pharmaceuticals & Healthcare Report Q2 2012
- Belgium Pharmaceuticals & Healthcare Report Q2 2012
- Italy Pharmaceuticals & Healthcare Report Q2 2012
- Croatia Pharmaceuticals & Healthcare Report Q2 2012
- Netherlands Pharmaceuticals & Healthcare Report Q2 2012
- Jordan Pharmaceuticals & Healthcare Report Q2 2012
- Egypt Pharmaceuticals & Healthcare Report Q2 2012
- Taiwan Pharmaceuticals & Healthcare Report Q2 2012